Trial Profile
A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Namilumab (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- Acronyms TELLUS
- Sponsors Takeda
- 13 Jun 2019 This trial has been completed in UK.
- 31 Aug 2018 Status changed from completed to discontinued.
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.